JAVELIN ANNOUNCES ACCEPTANCE OF MARKETING AUTHORIZATION ACCEPTANCE FOR DYLOJECT

Javelin Pharmaceuticals, Inc. announced today the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review the Marketing Authorization Application (MAA) for Dyloject(TM) (injectable diclofenac) for the treatment of patients with postsurgical pain.

Generic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1086748XSL_NEWSML_TO_NEWSML_WEB.xml)